Lantheus Medical Imaging has launched the first of two phase III clinical trials of a PET radiopharmaceutical for use in detecting coronary artery disease.
The study will evaluate the diagnostic efficacy of PET myocardial perfusion imaging (MPI) with flurpiridaz F-18 versus SPECT-based MPI for detecting significant coronary artery disease, the company said.
The phase III clinical development program will include two open-label trials with approximately 1,350 patients at 100 clinical trial sites worldwide, including locations in the U.S., Canada, Europe, and South America, according to Lantheus.
